Ace­po­dia un­corks a very ear­ly win for its an­ti­body-nat­ur­al killer cell con­ju­gates in HER2 tu­mors

Can the an­ti­body-drug con­ju­gate mod­el be ap­plied to an off-the-shelf NK cell ther­a­py? Ace­po­dia un­corked pre­lim­i­nary Phase I da­ta at #ES­MO21 that sug­gest the an­swer may be yes.

Pri­vate biotech Ace­po­dia’s lead “an­ti­body cell con­ju­ga­tion” (ACC) can­di­date ACE1702 was well-tol­er­at­ed in sev­en pa­tients with ad­vanced HER2 tu­mors who re­ceived low­er dos­es of the drug, CEO Son­ny Hsiao an­nounced ear­ly Thurs­day. The pa­tients who re­ceived the first four dose lev­els showed no signs of cy­tokine re­lease syn­drome, neu­ro­tox­i­c­i­ty or graft ver­sus host dis­ease — and one of them achieved a con­firmed par­tial re­sponse; not earth-shat­ter­ing, but a pos­i­tive sign.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER